Research programme: adenosine receptor modulators - Palobiofarma

Drug Profile

Research programme: adenosine receptor modulators - Palobiofarma

Alternative Names: e compound; PBF 1350; PBF 1472; PBF 1509; PBF-1129; PBF-1250; PBF-695; PBF-942

Latest Information Update: 28 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palobiofarma
  • Class
  • Mechanism of Action Adenosine A1 receptor agonists; Adenosine A1 receptor antagonists; Adenosine A2A receptor antagonists; Adenosine A2B receptor antagonists; Adenosine A3 receptor antagonists; Phosphodiesterase 10A inhibitors; Plasminogen activator inhibitors; Purinergic P1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Atrial fibrillation; Glaucoma; Psychiatric disorders

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Research Idiopathic thrombocytopenic purpura; IgA nephropathy; Lung cancer
  • Discontinued Atrial fibrillation; Glaucoma; Psychiatric disorders

Most Recent Events

  • 12 Sep 2017 Palobiofarma plans a phase I trial of PBF-1129 for Non-small cell lung cancer (Late-stage disease, Metastatic disease) (NCT03274479)
  • 28 Jan 2016 Discontinued - Preclinical for Glaucoma in Spain (PO)
  • 28 Jan 2016 Discontinued - Preclinical for Psychiatric disorders in Spain (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top